Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Allogene Therapeutics Inc (ALLO)

Allogene Therapeutics Inc (ALLO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 604,010
  • Shares Outstanding, K 209,000
  • Annual Sales, $ 100 K
  • Annual Income, $ -327,270 K
  • 60-Month Beta 0.86
  • Price/Sales 6,226.00
  • Price/Cash Flow N/A
  • Price/Book 1.13
Trade ALLO with:

Options Overview Details

View History
  • Implied Volatility 132.58% ( -3.30%)
  • Historical Volatility 97.70%
  • IV Percentile 76%
  • IV Rank 17.29%
  • IV High 678.39% on 05/17/24
  • IV Low 18.47% on 11/09/23
  • Put/Call Vol Ratio 0.01
  • Today's Volume 177
  • Volume Avg (30-Day) 237
  • Put/Call OI Ratio 0.48
  • Today's Open Interest 5,534
  • Open Int (30-Day) 4,989

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.35
  • Number of Estimates 12
  • High Estimate -0.28
  • Low Estimate -0.39
  • Prior Year -0.53
  • Growth Rate Est. (year over year) +33.96%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.01 +53.23%
on 07/05/24
3.67 -16.08%
on 07/16/24
+0.53 (+20.78%)
since 06/21/24
3-Month
2.01 +53.23%
on 07/05/24
3.67 -16.08%
on 07/16/24
-0.29 (-8.61%)
since 04/23/24
52-Week
2.01 +53.23%
on 07/05/24
5.78 -46.67%
on 03/08/24
-2.32 (-42.96%)
since 07/21/23

Most Recent Stories

More News
Allogene Therapeutics: Q1 Earnings Snapshot

Allogene Therapeutics: Q1 Earnings Snapshot

ALLO : 3.08 (+6.57%)
Allogene Therapeutics: Q4 Earnings Snapshot

Allogene Therapeutics: Q4 Earnings Snapshot

ALLO : 3.08 (+6.57%)
Allogene Therapeutics: Q3 Earnings Snapshot

Allogene Therapeutics: Q3 Earnings Snapshot

ALLO : 3.08 (+6.57%)
A Bull Market Is Coming: 1 Beaten-Down Growth Stock You Could Regret Not Buying on the Dip

Wall Street price targets suggest this stock can rocket more than 400% higher.

CRBU : 2.40 (+3.45%)
ALLO : 3.08 (+6.57%)
GILD : 71.17 (-1.71%)
Cantor Fitzgerald Bolsters Healthcare and Biotechnology Equity Research Team with Addition of Josh Schimmer, M.D., and Eric Schmidt, Ph.D.

/PRNewswire/ -- Cantor Fitzgerald, L.P., ("Cantor") a leading global financial services firm, today announced the addition of Josh Schimmer, M.D., and Eric...

ALLO : 3.08 (+6.57%)
Allogene Therapeutics: Q2 Earnings Snapshot

Allogene Therapeutics: Q2 Earnings Snapshot

ALLO : 3.08 (+6.57%)
3 Stocks With Sky-High Short Interest Levels

BYND, BTAI, and ALLO stand out as high short-interest stocks to watch due to their potential for price fluctuations and short-squeeze opportunities.

BTAI : 1.1900 (-0.83%)
BYND : 6.16 (unch)
ALLO : 3.08 (+6.57%)
CVNA : 129.11 (+0.17%)
RIVN : 17.50 (+1.63%)
ENVX : 16.20 (+6.23%)
Allogene Therapeutics: Q1 Earnings Snapshot

Allogene Therapeutics: Q1 Earnings Snapshot

ALLO : 3.08 (+6.57%)
Allogene Therapeutics: Q4 Earnings Snapshot

Allogene Therapeutics: Q4 Earnings Snapshot

ALLO : 3.08 (+6.57%)
Short Squeezes Have Returned in 2023 -- Here's Your Playbook

We haven't seen moves like these in a couple of years, so here's what investors should know.

GME : 25.50 (+1.11%)
CVNA : 129.11 (+0.17%)
SI : 1.2500 (+0.81%)
BBBY : 0.0751 (-27.09%)
ALLO : 3.08 (+6.57%)
MARA : 21.65 (-9.60%)
WMT : 70.65 (+0.38%)

Business Summary

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company, primarily focused on the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer.'

See More

Key Turning Points

3rd Resistance Point 3.47
2nd Resistance Point 3.29
1st Resistance Point 3.18
Last Price 3.08
1st Support Level 2.90
2nd Support Level 2.72
3rd Support Level 2.61

See More

52-Week High 5.78
Fibonacci 61.8% 4.34
Fibonacci 50% 3.89
Fibonacci 38.2% 3.45
Last Price 3.08
52-Week Low 2.01

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar